News
Mirati heads for FDA verdict on KRAS drug with new data
Mirati Therapeutics will hear from the FDA on its KRAS inhibitor adagrasib later this year, hoping to compete with first-to-market rival Lumakras from Amgen.
Thursday 28 November 2024
